You just read:

Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

News provided by

Shire plc

26 Apr, 2017, 06:00 BST